In this line, a clinically used therapy on NF-κB downstream targets uses inhibition of IL1beta in rheumatoid arthritis with recombinant IL-1 receptor antagonists such as anakinra [96]. The gene discussed is NFKB1; the disease is rheumatoid arthritis.